Rapport Therapeutics, Inc.
RAPP
$27.62
-$0.22-0.79%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -68.98% | -53.53% | -47.52% | -6.15% | -47.79% |
| Total Depreciation and Amortization | 1.92% | 16.89% | 21.15% | 60.53% | 390.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 31.96% | 298.99% | 183.85% | -50.18% | 237.60% |
| Change in Net Operating Assets | 168.98% | 875.26% | -2,639.84% | 86.28% | -31.02% |
| Cash from Operations | -70.99% | -6.40% | -53.31% | -14.89% | -39.48% |
| Capital Expenditure | 25.22% | 4.29% | 97.72% | 72.85% | 84.27% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -641.59% | -7.07% | 121.31% | 152.19% | 141.64% |
| Cash from Investing | -645.96% | -7.04% | 121.10% | 150.16% | 140.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4,342.86% | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -122.26% | -- | -- |
| Cash from Financing | 4,342.86% | 19,506.96% | -100.04% | -99.99% | 105.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,236.09% | 377.05% | -107.07% | -80.60% | 119.62% |